taspoglutide

The Swiss drugmaker expects an experimental medicine for Type 2 diabetes, called taspoglutide, to also boost growth over the coming years.

BusinessWeek.com -- 2010

Early this year, Roche pulled the plug on a diabetes drug, taspoglutide, after a costly investment in its late-stage development.

Guided By Genes, Shrinking Cancer Jonathan D. Rockoff 2011

The revamp was needed in the wake of the failure of more than half a dozen drugs in development, including the shelving of diabetes compound taspoglutide, which had promised to become a blockbuster with more than $1 billion in annual peak sales.

A Healthy Forecast for Pharma Goran Mijuk 2011

Patients taking taspoglutide suffered higher rates of nausea and vomiting of "mild to moderate intensity," and skin reactions at the site of injection, Roche said.

Blockbuster Odds Dim for Roche 2010

"Roche's suboptimal development for taspoglutide raises questions about the integrity of the development programs for their other large phase III programs," the bank said, singling out diabetes drug aleglitazar and cholesterol treatment dalceptrapib, two drugs that could also reach blockbuster status if they are approved.

Blockbuster Odds Dim for Roche 2010

The diabetes drug taspoglutide is developing according to plan and further data on the drug will be published within the course of 2010, Roche said.

Roche to Push Ahead on Cancer Treatments Julia Mengewein 2010

Clinical studies of Roche's drug, released over the weekend at the American Diabetes Association meeting in Orlando, Fla., showed taspoglutide to be as or more effective at lowering blood-sugar levels as some rival drugs, Roche said, but highlighted some side-effects that analysts and doctors called concerning.

Blockbuster Odds Dim for Roche 2010

Roche has estimated that taspoglutide could generate annual sales of more than 2 billion Swiss francs, if approved for sale.

Blockbuster Odds Dim for Roche 2010

Analysts estimate Roche has poured hundreds of millions of Swiss francs into clinical trials of the drug, taspoglutide, hoping it would help drive future sales amid a slowdown in the company's cancer treatment sales.

Blockbuster Odds Dim for Roche 2010

Earlier this month, Roche said it would amend its still ongoing clinical trial program for taspoglutide to closely monitor for such "hypersensitivity reactions," a change it said would likely delay the drug's filing with regulators such as the Food and Drug Administration by a year to 18 months.

Blockbuster Odds Dim for Roche 2010